Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson’s Disease Fluctuating Patients: Post hoc Analysesof Studies 016 and SETTLE
Background: Studies 016 and SETTLE showed that safinamide was safe and effective as adjunct therapy in patients with advanced Parkinson’s disease (PD) and motor fluctuations. The addition of safinamide to a stable dose of levodopa alone or with other antiparkinsonian medications significantly increa...
Main Authors: | Cattaneo, Carlo, Sardina, Marco, Bonizzoni, Ermino |
---|---|
Format: | Online |
Language: | English |
Published: |
IOS Press
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927927/ |
Similar Items
-
Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson’s Disease: A Post-Hoc Analysis
by: Cattaneo, Carlo, et al.
Published: (2015) -
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
by: Borgohain, Rupam, et al.
Published: (2014) -
Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
by: Loprete, Luca, et al.
Published: (2016) -
Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence
by: Bette S, et al.
Published: (2018-09-01) -
Emerging approaches in Parkinson’s disease – adjunctive role of safinamide
by: Müller, Thomas
Published: (2016)